Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus TAYTULLA.
ENOVID-E vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive